Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?

References

• Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24:296–304.
   PubMed Web of Science ®Google Scholar
• Sherif A, Holmberg L, Rintala E, Nordic Urothelial Cancer Group, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45:297–303.
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202–205. discussion 205-206.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778–792.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866.
   PubMed Web of Science ®Google Scholar
• McKnight JJ, Gray SB, O’Kane HF, et al. Apoptosis and chemotherapy for bladder cancer. J Urol. 2005;173:683–690.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265–7279.
   PubMed Web of Science ®Google Scholar
• Niedner H, Christen R, Lin X, et al. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol. 2001;60:1153–1160.
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626–629.
   PubMed Web of Science ®Google Scholar
• Farrow SN, Brown R. New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev. 1996;6:45–49.
   PubMed Web of Science ®Google Scholar
• Kluck RM, Bossy-Wetzel E, Green DR, et al. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science. 1997;275:1132–1136.
   PubMed Web of Science ®Google Scholar
• Zhao X-D, He Y-Y, Gao J, et al. High expression of Bcl-2 protein predicts favorable outcome in non-small cell lung cancer: evidence from a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15:8861–8869.
   PubMedGoogle Scholar
• Sekine I, Shimizu C, Nishio K, et al. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol. 2009;14:112–119.
   PubMed Web of Science ®Google Scholar
• Bouchalova K, Kharaishvili G, Bouchal J, et al. Triple negative breast cancer - BCL2 in prognosis and prediction. Review. Curr Drug Targets. 2014;15:1166–1175.
   PubMed Web of Science ®Google Scholar
• Hemdan T, Malmstrom PU, Jahnson S, et al. Emmprin expression predicts response and survival following cisplatin containing chemotherapy for bladder cancer: a validation study. J Urol. 2015;194:1575–1581.
   PubMed Web of Science ®Google Scholar
• Kiss B, Skuginna V, Fleischmann A, et al. Bcl-2 predicts response to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder. Urol Oncol 2015;33:166.e161–168.
   Web of Science ®Google Scholar
• Segersten MU, Edlund EK, Micke P, et al. A novel strategy based on histological protein profiling in-silico for identifying potential biomarkers in urinary bladder cancer. BJU Int. 2009;104:1780–1785.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.
   PubMed Web of Science ®Google Scholar
• Rodel C, Grabenbauer GG, Rodel F, et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys. 2000;46:1213–1221.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2015;68:959–967.
   PubMed Web of Science ®Google Scholar
• Groenendijk FH, de Jong J, Fransen van de Putte EE, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. 2016;69:384–388.
   PubMed Web of Science ®Google Scholar
• Ballman KV. Biomarker: predictive or prognostic? J Clin Oncol. 2015;33:3968–3971.
   PubMed Web of Science ®Google Scholar
• Cooke PW, James ND, Ganesan R, et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int. 2000;85:829–835.
   PubMed Web of Science ®Google Scholar
• Maluf FC, Cordon-Cardo C, Verbel DA, et al. Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Ann Oncol. 2006;17:1677–1686.
   PubMed Web of Science ®Google Scholar
• Gioacchini FM, Alicandri-Ciufelli M, Rubini C, et al. Prognostic value of Bcl-2 expression in squamous cell carcinoma of the larynx: a systematic review. Int J Biol Markers. 2015;30:e155–e160.
   PubMed Web of Science ®Google Scholar
• Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol. 1998;160:645–659.
   PubMed Web of Science ®Google Scholar
• Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8:128–136.
   PubMed Web of Science ®Google Scholar
• Uchida T, Minei S, Gao JP, et al. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. Oncol Rep. 2002;9:253–259.
   PubMed Web of Science ®Google Scholar
• Anagnostou VK, Welsh AW, Giltnane JM, et al. Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev. 2010;19:982–991.
   PubMed Web of Science ®Google Scholar